Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Anti-Aβ Antibodies on Immunometabolism in Early Alzheimer's Disease
ChiCTR2600127934Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of anti-β-amyloid monoclonal antibody in Alzheimer's disease (AD) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: TSPO(DPA714)-PET SUVR at 24 months. Started Jul 2026; status: recruiting.
02
Drugs
anti-β-amyloid monoclonal antibody
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2600127934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127934.